Literature DB >> 22285709

The burden of multidrug-resistant organisms on tertiary hospitals posed by patients with recent stays in long-term acute care facilities.

Dror Marchaim1, Teena Chopra, Christopher Bogan, Suchitha Bheemreddy, David Sengstock, Rajasekhar Jagarlamudi, Anurag Malani, Leslie Lemanek, Judy Moshos, Paul R Lephart, Kimberley Ku, Asma Hasan, Jiha Lee, Namir Khandker, Christopher Blunden, Sara F Geffert, Megan Moody, Rahbar Hiro, Yujing Wang, Farah Ahmad, Tarana Mohammadi, Omar Faruque, Diixa Patel, Jason M Pogue, Kayoko Hayakawa, Sorabh Dhar, Keith S Kaye.   

Abstract

BACKGROUND: Long-term acute care (LTAC) facilities admit patients with complex, advanced disease states. Study aims were to determine the burden posed on hospitals associated with LTAC exposure and analyze the differences between "present on admission" (POA) multidrug-resistant (MDR), gram-negative organisms (GNO) and POA MDR gram-positive organisms (GPO).
METHODS: A multicenter retrospective study was conducted in 13 hospitals from southeast Michigan, from September 1, 2008, to August 31, 2009. Cultures obtained in the first 72 hours of hospitalization (ie, POA) of MDR-GPO and MDR-GNO were reviewed. LTAC exposures in the previous 6 months and direct admission from a LTAC were recorded.
RESULTS: Overall, 5,297 patients with 7,147 MDR POA cultures were analyzed: 2,619 (36.6%) were MDR-GNO, and 4,528 (63.4%) were MDR-GPO. LTAC exposure in the past 6 months was present in 251 (5.2%) infectious episodes and was significantly more common among POA MDR-GNO than MDR-GPO (158 [8.6%] and 94 [3.1%], respectively, odds ratio, 2.87; P < .001). Recent LTAC exposure was strongly associated with both carbapenem-resistant Enterobacteriaceae (CRE) (31.6% of all CRE cases, P < .001) and Acinetobacter baumannii (14.9% of all A baumannii cases, P < .001).
CONCLUSION: Nearly 10% of MDR-GNO POA had recent LTAC exposure. Hospital efforts to control the spread of MDR-GNO should focus on collaborations and communications with referring LTACs and interventions targeted towards patients with recent LTAC exposure.
Copyright © 2012 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22285709     DOI: 10.1016/j.ajic.2011.09.011

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  14 in total

1.  Residence in Skilled Nursing Facilities Is Associated with Tigecycline Nonsusceptibility in Carbapenem-Resistant Klebsiella pneumoniae.

Authors:  David van Duin; Eric Cober; Sandra S Richter; Federico Perez; Robert C Kalayjian; Robert A Salata; Scott Evans; Vance G Fowler; Robert A Bonomo; Keith S Kaye
Journal:  Infect Control Hosp Epidemiol       Date:  2015-05-20       Impact factor: 3.254

Review 2.  Screening for carbapenem-resistant Enterobacteriaceae: Who, When, and How?

Authors:  Sandra S Richter; Dror Marchaim
Journal:  Virulence       Date:  2016-11-04       Impact factor: 5.882

3.  Nosocomial Outbreak of Extensively Drug-Resistant Acinetobacter baumannii Isolates Containing blaOXA-237 Carried on a Plasmid.

Authors:  Andrea M Hujer; Paul G Higgins; Susan D Rudin; Genevieve L Buser; Steven H Marshall; Kyriaki Xanthopoulou; Harald Seifert; Laura J Rojas; T Nicholas Domitrovic; P Maureen Cassidy; Margaret C Cunningham; Robert Vega; Jon P Furuno; Christopher D Pfeiffer; Zintars G Beldavs; Meredith S Wright; Michael R Jacobs; Mark D Adams; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

4.  The Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae Colonization and Infection among Long-Term Acute Care Hospital Residents.

Authors:  John P Mills; Naasha J Talati; Kevin Alby; Jennifer H Han
Journal:  Infect Control Hosp Epidemiol       Date:  2015-10-12       Impact factor: 3.254

5.  Dual-Function Potentiation by PEG-BPEI Restores Activity of Carbapenems and Penicillins against Carbapenem-Resistant Enterobacteriaceae.

Authors:  Hannah Panlilio; Anh K Lam; Neda Heydarian; Tristan Haight; Cassandra L Wouters; Erika L Moen; Charles V Rice
Journal:  ACS Infect Dis       Date:  2021-05-04       Impact factor: 5.084

Review 6.  Strategic measures for the control of surging antimicrobial resistance in Hong Kong and mainland of China.

Authors:  Vincent C C Cheng; Sally C Y Wong; Pak-Leung Ho; Kwok-Yung Yuen
Journal:  Emerg Microbes Infect       Date:  2015-02-11       Impact factor: 7.163

Review 7.  Reducing unnecessary urinary catheter use and other strategies to prevent catheter-associated urinary tract infection: an integrative review.

Authors:  Jennifer Meddings; Mary A M Rogers; Sarah L Krein; Mohamad G Fakih; Russell N Olmsted; Sanjay Saint
Journal:  BMJ Qual Saf       Date:  2013-09-27       Impact factor: 7.035

8.  Towards a Definition for Health Care-Associated Infection.

Authors:  N Deborah Friedman; Dana Levit; Eyal Taleb; Gil Marcus; Leah Michaeli; Mor Broide; Bethlehem Mengesha; Ronit Zaidenstein; Tsilia Lazarovitch; Mor Dadon; Keith S Kaye; Dror Marchaim
Journal:  Open Forum Infect Dis       Date:  2018-05-23       Impact factor: 3.835

9.  Gut Microbiota and Clinical Features Distinguish Colonization With Klebsiella pneumoniae Carbapenemase-Producing Klebsiella pneumoniae at the Time of Admission to a Long-term Acute Care Hospital.

Authors:  Anna M Seekatz; Christine M Bassis; Louis Fogg; Nicholas M Moore; Yoona Rhee; Karen Lolans; Robert A Weinstein; Michael Y Lin; Vincent B Young; Mary K Hayden
Journal:  Open Forum Infect Dis       Date:  2018-07-31       Impact factor: 3.835

10.  A Prospective Observational Study of the Epidemiology, Management, and Outcomes of Skin and Soft Tissue Infections Due to Carbapenem-Resistant Enterobacteriaceae.

Authors:  Oryan Henig; Eric Cober; Sandra S Richter; Federico Perez; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Steve Marshall; Susan D Rudin; T Nicholas Domitrovic; Andrea M Hujer; Kristine M Hujer; Yohei Doi; Scott Evans; Vance G Fowler; Robert A Bonomo; David van Duin; Keith S Kaye
Journal:  Open Forum Infect Dis       Date:  2017-07-27       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.